Hermanth Varghese
President at VENUS CONCEPT INC.
Net worth: 11 517 $ as of 31/03/2024
Hermanth Varghese active positions
Companies | Position | Start | End |
---|---|---|---|
VENUS CONCEPT INC. | Chief Operating Officer | 16/10/2023 | - |
President | 17/10/2022 | - |
Career history of Hermanth Varghese
Former positions of Hermanth Varghese
Companies | Position | Start | End |
---|---|---|---|
HLS THERAPEUTICS INC. | Chief Operating Officer | 01/04/2021 | 01/01/2022 |
Corporate Officer/Principal | 01/09/2017 | 01/04/2021 | |
ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 28/04/2014 | 31/12/2016 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director/Board Member | - | 06/06/2014 |
BAUSCH + LOMB CORPORATION | Corporate Officer/Principal | 01/01/2009 | 01/01/2014 |
BAUSCH HEALTH COMPANIES INC. | Corporate Officer/Principal | 01/01/2009 | 01/01/2014 |
Medical Discovery Management Corp.
Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Private Equity Analyst | 06/10/2006 | 06/10/2009 |
Private Equity Investor | 06/10/2006 | 06/10/2009 | |
MedTech Partners, Inc.
MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Private Equity Analyst | - | 05/10/2006 |
Private Equity Investor | - | 05/10/2006 | |
Biovail Corp.
Biovail Corp. Pharmaceuticals: MajorHealth Technology Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada. | Corporate Officer/Principal | - | - |
░░░░░ ░░░░░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
Training of Hermanth Varghese
University of Western Ontario | Doctorate Degree |
Statistics
International
Canada | 9 |
Ireland | 2 |
Switzerland | 2 |
Operational
Corporate Officer/Principal | 5 |
Private Equity Analyst | 2 |
Private Equity Investor | 2 |
Sectoral
Health Technology | 8 |
Finance | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 4 |
---|---|
BAUSCH HEALTH COMPANIES INC. | Health Technology |
HLS THERAPEUTICS INC. | Health Technology |
VENUS CONCEPT INC. | Health Technology |
BAUSCH + LOMB CORPORATION | Health Technology |
Private companies | 6 |
---|---|
Biovail Corp.
Biovail Corp. Pharmaceuticals: MajorHealth Technology Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Endo International Plc
Endo International Plc Pharmaceuticals: MajorHealth Technology Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland. | Health Technology |
MedTech Partners, Inc.
MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Finance |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Medical Discovery Management Corp.
Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Finance |
Litha Healthcare Group Ltd.
Litha Healthcare Group Ltd. BiotechnologyHealth Technology Litha Healthcare Group Ltd. develops pharmaceutical products and medical devices. The firm distributes products in three main sectors of the South African healthcare industry. It operates through following divisions; Litha Pharma, Medical and Biotech. The company was founded by Selwyn Kahanovitz in 1992 and is headquartered in Johannesburg, South Africa. | Health Technology |
- Stock Market
- Insiders
- Hermanth Varghese
- Experience